The M&A is small relative to PBH's ~$1.1B revenue base, and the refinancing increases annual interest cost by ~$4.5M. Monitor FQ1 earnings (Aug 6) for organic growth trends and LaCorium contribution details. Historical PBH reports show poor T+20 performance (avg -2.47%), so expect limited near-term upside despite the deal rationale.
Price Chart
Executive Summary
Prestige closed its $150M acquisition of LaCorium Health, priced a $400M 6.25% senior notes offering to refinance its 5.125% notes due 2028, and announced FQ1 2027 earnings release for August 6, 2026. The acquisition adds ~$40M revenue / ~$12M EBITDA Australian skincare business, while the refinancing extends debt maturity at higher interest cost (6.25% vs 5.125%) but removes near-term maturity risk. Net impact is mixed: accretive tuck-in M&A offset by higher interest expense and negative historical calibration on PBH filings.
Key Financial Metrics
Key Facts
- Acquired LaCorium Health for ~$150M cash on July 1, 2026
- LaCorium has ~$40M annual revenue, expected ~$12M EBITDA post-synergies
- Priced $400M 6.25% senior notes due 2034 to refinance existing 5.125% notes due 2028
- Notes sale expected to close July 15, 2026
- FQ1 2027 earnings release scheduled for August 6, 2026 before market open
- Approximately 75% of LaCorium sales in Australia; #1 lip care, #3 foot care positions
- Historical PBH filing reports show avg T+20 P&L -2.47% and 40% win rate
Financial Impact
< $0.5B total: $150M acquisition + $400M refinancing. EBITDA add ~$12M vs ~$1.1B market cap (~1% accretion pre-financing cost). Interest cost increase ~$4.5M/year ($400M × 112bps spread).
Risk Factors
- Higher interest expense from 6.25% notes vs 5.125% increases annual cash interest by ~$4.5M
- Integration risk for LaCorium, especially geographic/cultural differences (Australia vs US)
- PBH's historical filing reports show negative average alpha at T+20
- LaCorium's ~$12M EBITDA projection depends on achieving synergies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3322363 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | Press Release | $54.43 $52.56 | ▼ −3.44% | ▼ −4.04% | $45.26 (−16.85%) |
Jul 6, 2026 12w ago | Press Release | $48.86 $50.22 | ▲ +2.78% | ▲ +3.35% | $45.26 (−7.37%) |
Jun 16, 2026 15w ago | 8-K | $47.50 $47.19 | ▼ −0.65% | ▼ −0.85% | $45.26 (−4.72%) |
May 13, 2026 20w ago | 8-K | $45.93 $47.82 | ▼ −4.12% | ▼ −4.97% | $45.26 (+1.46%) |
May 7, 2026 21w ago | 144 | $54.59 $45.44 | ▼ −16.76% | ▼ −19.90% | $45.26 (−17.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access